Company Overview and News

 
First NZ cuts Michael Hill earnings forecast after weak sales

2018-10-16 nzherald.co.nz
First NZ Capital expects to see weaker earnings at Michael Hill International but says there is still potential for the share price to rise.
MHI MXRHY SFH MXRHF

 
Michael Hill struggles through transition as first quarter sales fall

2018-10-15 nzherald.co.nz
Michael Hill International is finding it harder to shift away from discount pricing than it anticipated, posting an 8.8 per cent decline in first-quarter sales.
MHI MXRHY SFH MXRHF

1
Michael Hill International names Daniel Bracken as new CEO

2018-09-20 nzherald.co.nz - 1
Michael Hill International has named the head of Specialty Fashion Group as its new chief executive.
MHI MXRHY SFH MXRHF

 
Michael Hill International Ltd. ADR 2018 Q4 - Results - Earnings Call Slides

2018-08-27 seekingalpha
The following slide deck was published by Michael Hill International Ltd. ADR in conjunction with their 2018 Q4 earnings call.
MHI MXRHY MXRHF

 
NZ shares hit record; Synlait, a2 gain while Sky TV, Z Energy drop

2018-08-27 nzherald.co.nz
New Zealand shares hit a record, led higher by Synlait Milk and a2 Milk Co while Sky Network Television continued Friday's decline.
MQBKY AIA MHI ZNRGF MXRHY MCQEF ACKDF ZEL AUKNY SKT ZNZ SYKWF AIA SKKTY SKLUY SKL MQG SML MXRHF

 
Michael Hill profit sinks 86 per cent on US exit

2018-08-26 nzherald.co.nz
Michael Hill International's full-year profit tumbled 86 per cent on Emma & Roe and US closure costs but the retailer says its new strategy has it positioned for growth.
MHI MXRHY MXRHF

1
Michael Hill lifts full-year revenue as it shifts focus back to core namesake brand

2018-07-10 nzherald.co.nz - 1
Michael Hill International increased revenue 3.3 per cent in its 2018 fiscal year as it opened more namesake brand stores in Australia and Canada, exited its US operations and began the closure of its Emma & Roe chain.
MHI MXRHY MXRHF

11
Shares rise after bumpy week, led by NZ Refining

2018-06-22 nzherald.co.nz
New Zealand shares rose, led by New Zealand Refining Company and Synlait Milk while Port of Tauranga and A2 Milk Co fell.
PPL FBU PUPKY MHI FCREY MXRHY NZR FRCEF SKT SYKWF PPSHY FBU SKKTY SML MXRHF

 
Michael Hill Jeweller pulls plug on low-cost brand

2018-06-22 radionz.co.nz
Jewellery retailer Michael Hill International will close its remaining Emma and Roe shops and concentrate on its core brand.
MHI MXRHY MXRHF

 
Michael Hill to close last Emma & Roe stores

2018-06-21 nzherald.co.nz
Michael Hill International said it plans to close the remaining six stores of its Emma & Roe chain as well as the sub-brand's online business.
MHI MXRHY MXRHF

11
A2 to join MSCI main stock index as Mercury drops off

2018-05-14 nzherald.co.nz
A review of global stock indices by MSCI will, as expected, add A2 Milk to the international investment advisor's main global index, with Mercury New Zealand to be removed.
BGR FBU MHI FBU THL FCREY MXRHY FRCEF MXRHF SML

11
Fletcher gains as stock stays in MSCI main index

2018-05-14 nzherald.co.nz
A review of global stock indices by MSCI has seen Fletcher Building shares gain after news the stock will remain on the international investment adviser's main global index, with A2 Milk rising on its planned entry and Mercury New Zealand dipping due to its planned removal.
BGR FBU MHI FBU THL FCREY MXRHY FRCEF MXRHF SML

1
Exit from US jewellery business to cost Michael Hill $6m

2018-04-11 nzherald.co.nz - 1
Michael Hill International said the exit from its US business is expected to cost US$4.5 million (NZ$6.1 million) for lease terminations and employee severance costs after it was unable to find a buyer for the jewellery stores.
MHI MXRHY MXRHF

Related Articles

ALIM: Alimera Sciences Analysis and Research Report

2018-10-01 - Asif

Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...

DMPI: DelMar Pharmaceuticals Analysis and Research Report

2018-09-25 - Asif

Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

Silicon Investor Message Boards

This table lists all message boards related to NZX:MHI / Michael Hill International on message board site Silicon Investor.

AMHI - American HealthChoice, Inc. AMHI - American HealthChoice, Inc. AMHI - American HealthChoice, Inc. UMHI - Universal Media Holdings, Inc. UMHI - Universal Media Holdings, Inc. UMHI - Universal Media Holdings, Inc.